Evotec SE (EVO) Long-Term Investments (2009 - 2026)
Evotec SE (EVO) reported Long-Term Investments of $5088.1 for Q1 2026, down 5.95% on a YoY basis from $5409.8 in Q1 2025, and down 5.57% sequentially from $5388.4 in Q4 2025.
Evotec SE (EVO) Long-Term Investments (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 10 years of Long-Term Investments data on file, last reported at $5088.1 in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments fell 5.95% year-over-year to $5088.1; the trailing twelve-month figure through Mar 2026 stood at $5088.1 (down 5.95% YoY), and the FY2025 full-year result was $5388.4, down 99.99% from the prior year.
- Long-Term Investments retreated to $5088.1 in Q1 2026, from $5388.4 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $133.7 million in Q4 2022 to a low of $3915.2 in Q1 2024.
- A 5-year average of $13.4 million and a median of $5818.4 in 2025 frame the typical range for Long-Term Investments.
- Across the five-year window, Long-Term Investments soared 1011.54% in 2024 and slumped 99.99% in 2025, its largest moves.
- Tracing EVO's Long-Term Investments over 5 years: stood at $133.7 million in 2022, then tumbled by 97.53% to $3.3 million in 2023, then soared by 1011.54% to $36.7 million in 2024, then tumbled by 99.99% to $5388.4 in 2025, then decreased by 5.57% to $5088.1 in 2026.
- Business Quant data shows EVO's Long-Term Investments at $5088.1 in Q1 2026, $5388.4 in Q4 2025, and $5818.4 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 5,088.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,088.06 |
| Dec 31, 2025 | 5,388.36 |
| Sep 30, 2025 | 5,818.39 |
| Jun 30, 2025 | 5,090.42 |
| Mar 31, 2025 | 5,409.84 |
| Dec 31, 2024 | 36.73 Mn |
| Sep 30, 2024 | 4,523.57 |
| Mar 31, 2024 | 3,915.25 |
| Dec 31, 2023 | 3.30 Mn |
| Dec 31, 2022 | 133.70 Mn |
| Sep 30, 2022 | 173,307.23 |
| Jun 30, 2022 | 200,784.86 |
| Mar 31, 2022 | 241,909.79 |
| Dec 31, 2021 | 307.49 Mn |
| Sep 30, 2021 | 357,858.28 |
| Dec 31, 2020 | 47.35 Mn |
| Dec 31, 2019 | 12.69 Mn |
| Sep 30, 2010 | 12.91 |
| Jun 30, 2010 | 12.75 |
| Mar 31, 2010 | 13.85 |